Ozempic has matured into the diabetes market leader in this class, with Trulicity close behind 2022 Ozempic sales were $8.5B vs
Among those who have taken GLP-1s, the most common reasons for doing so are to lose weight (70 percent), manage Type 2 diabetes (41 percent), or improve other health conditions such as blood pressure or cholesterol (24 percent)
doi: 10.1016/S0197-0186(01)00094-8
Cardiomyocyte/cardiac fibroblast dysfunction is related to abnormal proliferation, apoptosis, hypertrophy, as well as inflammation and fibrosis, which may be caused by mitochondrial dysfunction and metabolic disorders
Its popularity is mostly because of the high demand for natural weight loss supplements that can mimic the effects of popular GLP-1 drugs like Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide)